Effects of alprazolam on cortical activity and tremors in patients with essential tremor

PLoS One. 2014 Mar 25;9(3):e93159. doi: 10.1371/journal.pone.0093159. eCollection 2014.

Abstract

Background: Essential tremor (ET) is characterised by postural and action tremors with a frequency of 4-12 Hz. Previous studies suggest that the tremor activity originates in the cerebello-thalamocortical pathways. Alprazolam is a short-acting benzodiazepine that attenuates tremors in ET. The mechanisms that mediate the therapeutic action of alprazolam are unknown; however, in healthy subjects, benzodiazepines increase cortical beta activity. In this study, we investigated the effect of alprazolam both on beta and tremor-related cortical activity and on alterations in tremor presentation in ET patients. Therefore, we characterised the dynamics of tremor and cortical activity in ET patients after alprazolam intake.

Methods: We recorded hand tremors and contralateral cortical activity in four recordings before and after a single dose of alprazolam. We then computed the changes in tremors, cortico-muscular coherence, and cortical activity at the tremor frequency and in the beta band.

Results: Alprazolam significantly attenuated tremors (EMG: 76.2 ± 22.68%), decreased cortical activity in the tremor frequency range and increased cortical beta activity in all patients (P<0.05). At the same time, the cortico-muscular coherence at the tremor frequency became non-significant (P<0.05). We also found a significant correlation (r = 0.757, P<0.001) between the reduction in tremor severity and the increased ratio of cortical activity in the beta band to the activity observed in the tremor frequency range.

Conclusions: This study provides the first quantitative analysis of tremor reduction following alprazolam intake. We observed that the tremor severity decreased in association with an increased ratio of beta to tremor-related cortical activity. We hypothesise that the increase in cortical beta activity may act as a blocking mechanism and may dampen the pathological oscillatory activity, which in turn attenuates the observed tremor.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alprazolam / pharmacology*
  • Alprazolam / therapeutic use
  • Brain / drug effects*
  • Brain / physiopathology*
  • Electromyography
  • Essential Tremor / complications
  • Essential Tremor / drug therapy*
  • Essential Tremor / physiopathology*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Muscles / drug effects
  • Muscles / physiopathology
  • Tremor / complications
  • Tremor / drug therapy*

Substances

  • Alprazolam

Grants and funding

This work has been partially funded by CSIC, through the program for the incorporation of tenure researches CSIC-201050I040, “Development and clinical validation of a neuroprosthesis for tremor suppression”, and by the EU Commission through the grant EU-FP7-2011-287739, “NeuroTREMOR”. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.